Biologics drug development and manufacturing
Reliable and robust center of excellence for biologics CDMO and CRO services
Transform your groundbreaking discovery into a biologic that improves patients’ qualify of life with our state-of-the-art global network of biologics manufacturing facilities and comprehensive CDMO and CRO services. With more than 30 years of experience in process development, including more than 240 programs for biologics development as well as our expertise in cell line development, clinical manufacturing, and commercial manufacturing, we can nurture your molecule from lab to market—whether you bring your own cell line, media, and process, or take advantage of our world-class ecosystem.
Our commitment to excellence is reflected in our rigorous quality control processes, commitment to regulatory adherence, cutting-edge technology, and dedicated team of experts. Partner with us to leverage our reliable platforms and expertise to accelerate your journey towards delivering transformative healthcare solutions.
14 drugs with approved BLAs
Patheon pharma services has worked on 14 drugs with approved BLAs in the US over the past five years (2018-2022).
60 customers in 14 countries
From 2018-2022, we worked on biologics projects with over 60 customers across 14 countries.
810+ biologics batches
From 2018-2023, 810+ biologics batches manufactured globally including commercial, clinical, and process performance qualification (PPQ).
70% of projects for mAb products
From 2018-2022, 70% of our new Biologics projects were for monoclonal antibody (mAb) products.
Explore our biologic services and integrated solutions:
Explore our state-of-the-art global network of biologics manufacturing facilities, where innovation meets precision to produce life-changing therapies
Thermo Fisher Scientific's biologics facility in St. Louis, MO is a center of excellence in single-use bioreactor technology that specializes in mammalian cell development, process development, analytics, and end-to-end cGMP manufacturing services.
Explore our facility in St. Louis, MO
Thermo Fisher Scientific’s site in Brisbane, Australia is a state-of-the-art facility, specializing in clinical and commercial manufacturing services, including clinical cGMP manufacturing.
Explore our facility in Brisbane, Australia
Thermo Fisher Scientific’s site in Groningen, Netherlands specializes in preclinical and commercial cGMP manufacturing and scale-up of mammalian cell culture, recombinant proteins, and monoclonal antibodies.
Explore our site in Groningen, Netherlands
Thermo Fisher Scientific’s facility in Lengnau, Switzerland specializes in highly flexible bioproduction technologies, including single-use bioreactors up to 5,000 L and stainless steel bioreactors up to 12,500 L, providing a pathway from development to large-scale production as your manufacturing needs evolve.
Explore our site in Lengnau, Switzerland
Meet with our dedicated experts who will work tirelessly to bring your groundbreaking biologic from concept to reality
Elena Gontarz, PhD, St. Louis, Missouri, USA
Holding her PhD in biochemistry with over 10 years of experience in developing biologics for pharma companies, Dr. Gontarz is our resident expert in global analytical and process development, as well as formulation sciences. Currently, Dr. Gontarz is the Head of the Scientific and Technical Affairs team, leading CMC support and biologics programs from Phase I to commercial manufacturing. Meet with Dr. Gontarz to learn more about our analytical method lifecycle development, cell line development, process development, tech transfer, and late phase commercialization.
Palak Patel, St. Louis, Missouri, USA
With over 5 years of experience in early phase biologic development and delivering innovative solutions for pharma companies, Palak is one of our Scientific and Technical Affairs subject matter experts in cell line and cell culture development for biologics. Meet with Palak to uncover how our early phase biologics solutions can help you get your biologic to patients faster.
Otto P.J. Jurrius, Groningen, Netherlands
Holding his master’s degree in biotechnology with over two decades of biopharmaceutical industry experience, Otto is the General Manager at Thermo Fisher Scientific’s biologics manufacturing site in Groningen, Netherlands. Otto leads biologics project management, manufacturing, engineering, and general management across biologics development, as well as clinical and commercial manufacturing. Meet with Otto to learn more about our innovative clinical and commercial manufacturing capabilities.
Erica Byerley, Lengnau, Switzerland
With over 8 years of experience and degrees in both chemical engineering and biological sciences, Erica is our guru in single-use technology, technology transfer, process design, and operational readiness for biologics development through clinical manufacturing. Erica currently leads our global tech transfer engineering team at our brand-new facility in Lengnau, Switzerland. Meet with Erica to learn about our innovative single-use bioreactors or engineering designs that can accelerate your biologics development journey.
Kym Baker, PhD, Brisbane, Australia
Holding her PhD in immuno-vaccine development with over 30 years of experience in developing and manufacturing biologics for pharma companies, Kym has worked on over 400 biologics with 10 through to product commercialization. Currently, Kym leads our award-winning, globally regulatory-approved biologics manufacturing facility in Brisbane, Australia, serving client programs from Phase I to commercial manufacturing. Meet with Kym to learn more about how we can support your products' lifecycle from tech transfer to clinical and late-phase commercialization and manufacturing, or how R&D tax credit and the Clinical Trial Notification (CTN) Scheme in Australia can help accelerate your early phase product to market.